David Einspahr, MD
Hematology & Oncology · Topeka, KSNPI 1780634923
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Astellas Pharma US Inc at 32.5% of the total. Reporting peaked in 2019 at $286 and has fallen 91.7% since, to $24 in 2022. That places this record below the midpoint for hematology & oncology clinicians in KS, where the typical reported total is $1,410.
Across 18 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$114
- E.r. Squibb & Sons, L.L.C.$41
- Gilead$30
- Karyopharm Therapeutics Inc.$24
- Pfizer$23
- Lilly USA, LLC$18
- plus $101 from 7 others
Across 60 payments — averaging $958.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$23K
- EMD Serono, Inc.$10K
- Pharmacyclics LLC, An Abbvie Company$9K
- Chiesi USA, Inc.$7K
- Incyte Corporation$4K
- Novocure Inc.$4K
What the payments were for
- Food & beverage$20057%
- Education$15043%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $114 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Gilead | 2 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Pfizer | 2 | $23 |
| Lilly USA, LLC | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Merck | 1 | $16 |
| Novartis | 1 | $15 |
| Amgen | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$350 in reported general payments places this provider in the 20th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 68 | $1,022,967 |
| ImbruvicaIbrutinib | 32 | $697,912 |
| CalquenceAcalabrutinib Maleate | 18 | $265,845 |
| BosulifBosutinib | 12 | $235,989 |
| VenclextaVenetoclax | 15 | $141,035 |
| ThalomidThalidomide | 11 | $81,773 |
| EliquisApixaban | 53 | $33,177 |
| Enoxaparin Sodium | 11 | $6,457 |
| Imatinib Mesylate | 24 | $3,253 |
| Hydroxyurea | 76 | $2,090 |
| Anagrelide Hcl | 20 | $2,087 |
| Potassium Chloride | 27 | $1,105 |
| Anastrozole | 88 | $1,083 |
| Doxycycline Monohydrate | 12 | $549 |
| Letrozole | 21 | $405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerBosulif, Eliquis | $23 | $269,16665 claims |
| AbbVieVenclexta | $13 | $141,03515 claims |
| Lilly USA, LLCOlanzapine | $18 | $25117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Topeka
- Asha MurthyTopeka$3K
- Yaman AlaliTopeka$1K
- Mehmood HashmiTopeka$985
- Brandon WeckbaughTopeka$912
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Marc HoffmannOverland Park$153K
- Priyanka SharmaWestwood$135K
- Jeffrey WeitzelKansas City$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.